stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) Return on equity
Alkermes plc's return on equity over the twelve months to 30 September 2026 was −0.02%, down 14.7 percentage points from fiscal 2025 (14.7%). Over the past ten years it has ranged from −17.4% (fiscal 2019) to 31.7% (fiscal 2023); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 14.7% | (12.80) |
| FY2024 | 27.5% | (4.15) |
| FY2023 | 31.7% | 46.35 |
| FY2022 | −14.7% | (10.26) |
| FY2021 | −4.42% | 5.88 |
| FY2020 | −10.3% | 7.13 |
| FY2019 | −17.4% | (5.69) |
| FY2018 | −11.7% | 1.36 |
| FY2017 | −13.1% | 3.42 |
| FY2016 | −16.5% | 0.24 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LQDA Liquidia Corporation compare | 131.8% |
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| ALKS Alkermes plc | −0.02% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| SUPN Indivior Pharmaceuticals Inc. compare | −337.8% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ALKS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement